| P&L Statement | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 3037 | 3069 | 3325 |
| Cost of Material Consumed | 1923 | 1697 | 1932 |
| Change in Inventory | 18 | 137 | -74 |
| Gross Margins | 36.09 | 40.24 | 44.12 |
| Employee Benefit Expenses | 202 | 219 | 257 |
| Other Expenses | 514 | 534 | 668 |
| EBITDA | 380 | 442 | 542 |
| OPM | 12.51 | 14.4 | 16.3 |
| Other Income | 93 | 108 | 165 |
| Finance Cost | 46 | 39 | 25.5 |
| D&A | 87 | 89 | 91.7 |
| EBIT | 293 | 353 | 450.3 |
| EBIT Margins | 9.65 | 11.5 | 13.54 |
| PBT | 339 | 422 | 589 |
| PBT Margins | 11.16 | 13.75 | 17.71 |
| Tax | 97 | 90 | 137 |
| PAT | 242 | 332 | 452 |
| NPM | 7.97 | 10.82 | 13.59 |
| EPS | 113.62 | 155.87 | 198.86 |
| Financial Ratios | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Profit Margin | 12.51 | 14.4 | 16.3 |
| Net Profit Margin | 7.97 | 10.82 | 13.59 |
| Earning Per Share (Diluted) | 113.62 | 155.87 | 198.86 |
| Assets | 2023 | 2024 | 2025 |
|---|---|---|---|
| Fixed Assets | 698 | 687 | 651 |
| CWIP | 150 | 138 | 140 |
| Investments | 1464 | 2333 | 4768 |
| Trade Receivables | 758 | 903 | 1109 |
| Inventory | 689 | 525 | 584.5 |
| Other Assets | 373.5 | 571 | 750.5 |
| Total Assets | 4132.5 | 5157 | 8003 |
| Liabilities | 2023 | 2024 | 2025 |
|---|---|---|---|
| Share Capital | 21.3 | 21.3 | 22.73 |
| FV | 10 | 10 | 10 |
| Reserves | 2896 | 3973 | 3476 |
| Borrowings | 559 | 363 | 237 |
| Trade Payables | 439 | 477 | 521 |
| Other Liabilities | 217.2 | 322.7 | 3746.27 |
| Total Liabilities | 4132.5 | 5157 | 8003 |
| Cash-Flow Statement | 2023 | 2024 | 2025 |
|---|---|---|---|
| PBT | 295 | 364 | 589 |
| OPBWC | 410 | 470 | 575 |
| Change in Receivables | 26 | -142 | -203 |
| Change in Inventories | -47 | 164 | -59 |
| Change in Payables | -371 | 42 | 84 |
| Other Changes | -2 | -15 | -29 |
| Working Capital Change | -394 | 49 | -207 |
| Cash Generated From Operations | 16 | 519 | 368 |
| Tax | -83 | -93 | -136 |
| Cash Flow From Operations | -67 | 426 | 232 |
| Purchase of PPE | -86 | -66 | -79 |
| Sale of PPE | 1 | 1 | 0.5 |
| Cash Flow From Investment | 1 | 48 | -12 |
| Borrowing | -130 | -195 | -128.4 |
| Dividend | -9 | -21 | -27.28 |
| Equity | 0 | 0 | 36.27 |
| Others From Financing | -45 | -41 | -24.59 |
| Cash Flow from Financing | -184 | -257 | -144 |
| Net Cash Generated | -250 | 217 | 76 |
| Cash at the Start | 391 | 140 | 358 |
| Cash at the End | 141 | 357 | 434 |
Indofil Industries Limited is a leading agrochemical and specialty chemical company with a strong presence in both domestic and international markets. Established as part of the K.K. Modi Group, the company has built a diversified portfolio comprising fungicides, insecticides, herbicides, plant growth regulators, and industrial chemicals. Indofil is particularly known for its flagship fungicide Mancozeb, where it has earned a dominant reputation as one of the world’s largest manufacturers and exporters. With state-of-the-art manufacturing facilities, extensive R&D capabilities, and a customer-centric approach, the company consistently delivers high-quality chemical solutions that cater to farmers, industrial clients, and global formulators alike.
From a business standpoint, Indofil Industries benefits from its integrated operations, strong supply chain, and ability to innovate across both agricultural and industrial chemical segments. The company actively invests in research and development to create advanced formulations suited to diverse crops, climatic conditions, and pest challenges. Its global footprint spans more than 100 countries, supported by long-term partnerships, effective distribution networks, and compliance with international regulatory standards. Indofil also emphasizes sustainable practices, including efficient resource management, environmentally responsible manufacturing, and farmer education programs aimed at promoting safe and effective agrochemical usage. These efforts strengthen the company’s brand reputation and reinforce its competitive positioning in an increasingly regulated industry.
In the unlisted market, Indofil Industries Limited’s shares attract investor interest due to its strong global presence, consistent demand for agrochemicals, and balanced revenue streams across agriculture and specialty chemicals. The company’s leadership in Mancozeb production, expansion into high-value chemical segments, and focus on innovation provide a solid foundation for long-term growth. Additionally, rising global food demand, increased agricultural productivity requirements, and India's growing export opportunities create favorable conditions for the agrochemical sector. For investors seeking exposure to a resilient, export-driven, and diversified chemical business, Indofil’s unlisted shares present a compelling investment opportunity backed by strong fundamentals and a track record of sustainable performance.
Q:1 How do I confirm the booking of Indofil Industries Limited Unlisted Shares?
Answer: You can confirm the booking by contacting us at the trading price for the shares you wish to purchase.
Q:2 What documents do I need to provide to buy Indofil Industries Limited Unlisted Shares?Answer: You need to provide your client master report, PAN Card, and a Cancelled Cheque, especially if you are not transferring funds from the bank account mentioned in your CMR Copy.
Q:3 Why do I need to submit KYC documents?
Answer: KYC documents are required as per SEBI regulations to ensure compliance and verify your identity.
Q:4 How will I receive the bank details for the payment?
Answer: We will provide you with the necessary bank details once you confirm your booking.
Q:5 What payment methods are accepted for purchasing shares?
Answer: Payments must be made via RTGS, NEFT, IMPS, or cheque transfer.Cash deposits are not accepted.
Q:6 Can I make a cash deposit for the purchase of shares?
Answer: No, cash deposits are not allowed.You must use electronic transfer methods or cheque.
Q:7 From which bank account should I make the payment?
Answer: The payment must be made from the same bank account to which the shares will be credited.
Q:8 What happens if I do not have a client master report?
Answer: If you do not have a client master report, you can ask your broker for one, as it is necessary for the transaction.